

YR0023

Leader in Biomolecular Solutions for Life Science



Human CD123 Monoclonal Antibody

Catalog No.: YR0023

Basic Information

Molecular Weight

150 kDa

Endotoxin

<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay

Sterility

0.2 μm filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone

Pivekimab Biosimilar

Isotype

Human IgG1 kappa

Immunogen

Recommended Isotype Control(s)

Recommended Dilution Buffer

1×PBS pH 7.3

Contact



www.abclonal.com

Product Information

Production

Purified from cell culture supernatant in an animal-free facility


Purification

Protein A or G purification


Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

Validation Data



Direct ELISA binding curve demonstrating the recognition of Human Anti-Human CD123 (Research Grade Pivekimab Biosimilar) Monoclonal Antibody to CD123. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.



Human CD123 SPR assay. Determined through SPR assay, the Human Anti-Human CD123 (Research Grade Pivekimab Biosimilar) Monoclonal Antibody is Capable of binding to Human Trop-2 with an affinity constant of 43.22pM.